
    
      538 Patients with resectable (cT4cN0 or cT1-4 and cN+, cM0) adenocarcinoma of the stomach or
      the esophagogastric junction without previous therapy will be included in this study. After
      randomization patients receive perioperatively 4 cycles FLOT or FOLFIRINOX, followed by a
      restaging of the tumour status and surgery. Subsequently another 4 cycles of FLOT or
      FOLFIRNOX are applicated.
    
  